<SEC-DOCUMENT>0000925421-18-000259.txt : 20180718
<SEC-HEADER>0000925421-18-000259.hdr.sgml : 20180718
<ACCEPTANCE-DATETIME>20180718161752
ACCESSION NUMBER:		0000925421-18-000259
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20180716
FILED AS OF DATE:		20180718
DATE AS OF CHANGE:		20180718

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Novartis Bioventures Ltd
		CENTRAL INDEX KEY:			0001297709
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38130
		FILM NUMBER:		18958603

	BUSINESS ADDRESS:	
		STREET 1:		C/O NOVARTIS INTERNATIONAL AG
		STREET 2:		WSJ-200.220
		CITY:			CH-4002 BASEL
		STATE:			V8
		ZIP:			0000000000
		BUSINESS PHONE:		41-61-324-6210

	MAIL ADDRESS:	
		STREET 1:		C/O NOVARTIS INTERNATIONAL AG
		STREET 2:		WSJ-200.220
		CITY:			CH-4002 BASEL
		STATE:			V8
		ZIP:			0000000000

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			NOVARTIS AG
		CENTRAL INDEX KEY:			0001114448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38130
		FILM NUMBER:		18958604

	BUSINESS ADDRESS:	
		STREET 1:		LICHTSTRASSE 35
		CITY:			BASEL
		STATE:			V8
		ZIP:			CH 4056
		BUSINESS PHONE:		01141613241111

	MAIL ADDRESS:	
		STREET 1:		LICHTSTRASSE 35
		CITY:			BASEL
		STATE:			V8
		ZIP:			CH 4056

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AILERON THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001420565
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		281 ALBANY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		617-995-0900

	MAIL ADDRESS:	
		STREET 1:		281 ALBANY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>edgar.xml
<DESCRIPTION>PRIMARY DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2018-07-16</periodOfReport>

    <issuer>
        <issuerCik>0001420565</issuerCik>
        <issuerName>AILERON THERAPEUTICS INC</issuerName>
        <issuerTradingSymbol>ALRN</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001297709</rptOwnerCik>
            <rptOwnerName>Novartis Bioventures Ltd</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O NOVARTIS INTERNATIONAL AG</rptOwnerStreet1>
            <rptOwnerStreet2>WSJ-200.220</rptOwnerStreet2>
            <rptOwnerCity>BASEL</rptOwnerCity>
            <rptOwnerState>V8</rptOwnerState>
            <rptOwnerZipCode>CH-4002</rptOwnerZipCode>
            <rptOwnerStateDescription>SWITZERLAND</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001114448</rptOwnerCik>
            <rptOwnerName>NOVARTIS AG</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>LICHTSTRASSE 35</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>BASEL</rptOwnerCity>
            <rptOwnerState>V8</rptOwnerState>
            <rptOwnerZipCode>CH 4056</rptOwnerZipCode>
            <rptOwnerStateDescription>SWITZERLAND</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2018-07-16</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>300</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>5.15</value>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>2543882</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                    <footnoteId id="F2"/>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2018-07-17</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>12500</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>4.71</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>2531382</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                    <footnoteId id="F2"/>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">Reflects sales of common stock executed in multiple transactions at prices ranging from $5.14 to $5.16. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.</footnote>
        <footnote id="F2">The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities.</footnote>
    </footnotes>

    <remarks>Exhibit List - Exhibit 24 - Power of Attorney</remarks>

    <ownerSignature>
        <signatureName>/s/ Bartosz Dzikowski, Secretary of the Board of Novartis Bioventures Ltd</signatureName>
        <signatureDate>2018-07-18</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>/s/ Stephan Sandmeier, Authorized Signatory on behalf of Novartis Bioventures Ltd</signatureName>
        <signatureDate>2018-07-18</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>/s/ Bartosz Dzikowski, Authorized Signatory on behalf of Novartis AG</signatureName>
        <signatureDate>2018-07-18</signatureDate>
    </ownerSignature>

    <ownerSignature>
        <signatureName>/s/ Stephan Sandmeier, Authorized Signatory on behalf of Novartis AG</signatureName>
        <signatureDate>2018-07-18</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>poa071818.htm
<DESCRIPTION>POWER OF ATTORNEY
<TEXT>
<HTML><BODY><PRE>Exhibit 24



   POWER OF ATTORNEY



 We, the undersigned, under the authority granted to each of us to sign jointly

on behalf of Novartis AG, hereby grant powers to Stephan Sandmeier, Bartosz Dzikowski,

Anja Konig, Marc Ceulemans, Florian Muellershausen, Beat Steffen and Florent Gros and

constitute and appoint any two of them jointly as our true and lawful attorneys and

representatives and to act on our behalf and to sign filings to be made with the U.S.

Securities and Exchange Commission (the "SEC") relating to the shares of Aileron

Therapeutics, Inc. held by Novartis Bioventures Ltd, an indirect subsidiary of Novartis AG,

as required by the SEC (the "SEC Filings"), and to undertake and carry out all tasks and

formalities on our behalf which may be required in connection with giving effect to the SEC

Filings.



 We, the undersigned, undertake to ratify and confirm whatever our true and

lawful attorneys do or purport to do in good faith in the exercise of any power conferred by

this Power of Attorney.



 We, the undersigned, declare that a person who deals with our true and lawful

attorneys in good faith may accept a written statement signed by such attorneys to the effect

that this Power of Attorney has not been revoked as conclusive evidence of that fact.



 The authority granted by this Power of Attorney shall expire immediately

after the date on which the SEC Filings are no longer required and, as to each individual,

upon the date on which such individual is no longer employed by Novartis AG or any

subsidiary thereof.



 IN WITNESS WHEREOF, this Power of Attorney is duly signed on this

12th day of July 2018.





    Novartis AG



    By: /s/ Jean-Baptiste Emery

    Name: Jean-Baptiste Emery

    Title: Authorized Signatory



    By: /s/ Felix Eichhorn

    Name: Felix Eichhorn

    Title: Authorized Signatory

</PRE></BODY></HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
